Available as an add-on in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers include cCD3, cCD22, CD33, CD34, CD45, CD79a, cMPO and nTdT.

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), TP53 (17p13.1), IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16), IGH/MAFB t(14;20) are included in the Myeloma FISH Profile.

Cytogenetic abnormalities commonly associated with myeloproliferative neoplasms (MPN) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), BCR/ABL1-ASS1 t(9:22), 13q (13q-/-13), 20q (20q-) are included in the MPN FISH Profile

Rearrangements of the PDGFRA (4q12), PDGFRB (5q32), and FGFR1 (8p11) genes are detected by fluorescence in situ hybridization (FISH).

Cytogenetic abnormalities commonly associated with myelodysplastic syndrome (MDS) are detected by fluorescence in situ hybridization (FISH). Probes for MECOM (3q26.2), 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), KMT2A (MLL)(11q23.3), ETV6 (12p13.2), TP53 (17p13.1), Cen 19 (+19), 20q (20q-) are included in the MDS Extended FISH Profile (Extended).

Cytogenetic abnormalities commonly associated with myelodysplastic syndrome (MDS) are detected by fluorescence in situ hybridization (FISH). Probes for 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), KMT2A (MLL)(11q23.3), 20q (20q-) are included in the MDS Standard FISH Profile.

Chromosomal gains, losses, deletions, inversions, or translocations commonly associated with various hematological disorders and solid tumors are detected by fluorescence in situ hybridization (FISH).

Chromosomal gains, losses, deletions, inversions, or translocations commonly associated with various hematological disorders and solid tumors are detected by chromosome analysis.

Preparation of blood smears and/or bone marrow core/clot for staining, morphological identification and enumeration of hematopoietic cells.

Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.